Back to rankings

Bruker Corporation (BRKR)

NEUTRAL
HealthcareMedical DevicesUnited States

Fundamental

40

Price

$57.62

Market Cap

$8.94B

Part 1 · What the company is worth

Overview

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balance Sheet & Liquidity

Revenue

$3.50B

Trailing 12 months (through 6/30/2026)

Net Income

$-71M

Trailing 12 months (through 6/30/2026)

Free Cash Flow

$43M

Total Equity

$2.46B

Total Liabilities

$3.73B

Current Ratio

1.85

Interest Coverage

0.50

Debt/EBITDA

6.33

Earnings Per Share

Revenue & Net Income

Free Cash Flow

Income Breakdown

Historical statement

Margins over time

Debt over time

How heavy the debt is

Growth grid

Growth — Revenue

Fair Value Estimation

Overvalued

Fair Value

$44.24

Current Price

$57.62

Margin of Safety

-30.2%

Fair Value Range

$28.76 - $59.73

Estimation Methods

Analyst Target:$58.75
DCF:$24.90
PE-based:-
Graham Growth:-
EPV:-
Analyst Consensus:Buy (14B / 6H / 1S)
Last Earnings Surprise:+24.87%

Valuation Metrics

P/E Ratio

-

ROE

-0.4%

P/B Ratio

3.62

P/FCF

92.45

Gross Margin

46.4%

ROIC

-0.5%

Profitability Radar

Value Creation (Economic Moat)

ROIC

-0.5%

WACC

9.8%

ROIC − WACC

-10.3 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Fundamental Analysis Criteria

Passed (10)

  • Price CAGR 10.89%
  • Gross Margin 46.4%
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • Current Ratio
  • Revenue Growth 5Y 11.6%
  • Analyst Consensus 67% Buy
  • Earnings Surprise avg 19.0%
  • Share Dilution -61.5%
  • Piotroski F-Score 5/9

Failed (13)

  • EPS shows upward trend
  • ROIC -0.5%
  • P/FCF 92.45
  • P/B Ratio 3.62
  • Operating Margin -0.9%
  • CapEx intensity
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • DCF valuation (Overvalued)
  • ROE -2.9%
  • Net Margin Trend -2.0% vs 2.3%

Unavailable (4)

  • Dividend Payout NaN%
  • Price below Graham Number
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)

Piotroski F-Score

5/9

Mixed signals: some areas need attention

score
criteria

Earnings Quality

-

Low quality: investigate accounting

Share Dilution

-61.5%

Buying back shares. Shareholder friendly

Governance

Executive Team

NameTitleAge
Dr. Frank H. Laukien Ph.D.Chairman, CEO & President65
Dr. Mark R. Munch Ph.D.Corporate Executive VP and President of Bruker Nano Group & Corporate63
Dr. Falko Busse Ph.D.President of Bruker BioSpin Group58
Dr. Burkhard Prause Ph.D.President and CEO of Bruker Energy & Supercon Technologies, Inc.58

Audit Risk

7

Board Risk

6

Compensation Risk

6

Shareholder Rights Risk

4

Part 2 · The price and when to enter

This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.

Latest News

Recent headlines for BRKR, sourced from Markets Gazette.

No recent news for BRKR.